Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma

Choroidal osteoma is an uncommon benign osseous intraocular tumor that typically affects young adult women. Choroidal neovascularization (CNV) is one of the complications that can develop in eyes with choroidal osteoma. We present a case of CNV secondary to choroidal osteoma treated with intravitrea...

Full description

Bibliographic Details
Main Authors: Zenith H.Y. Wu, Michelle Y.Y. Wong, Timothy Y.Y. Lai
Format: Article
Language:English
Published: Karger Publishers 2012-06-01
Series:Case Reports in Ophthalmology
Subjects:
Online Access:http://www.karger.com/Article/FullText/339624
id doaj-1f8efcb03a074e788cf288effad4612e
record_format Article
spelling doaj-1f8efcb03a074e788cf288effad4612e2020-11-24T23:28:43ZengKarger PublishersCase Reports in Ophthalmology1663-26992012-06-013220020410.1159/000339624339624Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal OsteomaZenith H.Y. WuMichelle Y.Y. WongTimothy Y.Y. LaiChoroidal osteoma is an uncommon benign osseous intraocular tumor that typically affects young adult women. Choroidal neovascularization (CNV) is one of the complications that can develop in eyes with choroidal osteoma. We present a case of CNV secondary to choroidal osteoma treated with intravitreal ranibizumab. A 57-year-old lady presented with painless loss of vision with a right-eye visual acuity of 20/800. Fundus examination showed a well-demarcated yellowish peripapillary choroidal osteoma with associated retinal and subretinal hemorrhage due to CNV. Three intravitreal ranibizumab injections at monthly intervals were given and her visual acuity improved to 20/30 following treatment. After 1.2 years of follow-up, the right eye visual acuity was maintained at 20/30 with no evidence of CNV recurrence. Our findings suggest that intravitreal ranibizumab may be an effective therapeutic option for treating CNV secondary to choroidal osteoma.http://www.karger.com/Article/FullText/339624RanibizumabChoroidal osteomaChoroidal neovascularization
collection DOAJ
language English
format Article
sources DOAJ
author Zenith H.Y. Wu
Michelle Y.Y. Wong
Timothy Y.Y. Lai
spellingShingle Zenith H.Y. Wu
Michelle Y.Y. Wong
Timothy Y.Y. Lai
Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma
Case Reports in Ophthalmology
Ranibizumab
Choroidal osteoma
Choroidal neovascularization
author_facet Zenith H.Y. Wu
Michelle Y.Y. Wong
Timothy Y.Y. Lai
author_sort Zenith H.Y. Wu
title Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma
title_short Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma
title_full Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma
title_fullStr Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma
title_full_unstemmed Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma
title_sort long-term follow-up of intravitreal ranibizumab for the treatment of choroidal neovascularization due to choroidal osteoma
publisher Karger Publishers
series Case Reports in Ophthalmology
issn 1663-2699
publishDate 2012-06-01
description Choroidal osteoma is an uncommon benign osseous intraocular tumor that typically affects young adult women. Choroidal neovascularization (CNV) is one of the complications that can develop in eyes with choroidal osteoma. We present a case of CNV secondary to choroidal osteoma treated with intravitreal ranibizumab. A 57-year-old lady presented with painless loss of vision with a right-eye visual acuity of 20/800. Fundus examination showed a well-demarcated yellowish peripapillary choroidal osteoma with associated retinal and subretinal hemorrhage due to CNV. Three intravitreal ranibizumab injections at monthly intervals were given and her visual acuity improved to 20/30 following treatment. After 1.2 years of follow-up, the right eye visual acuity was maintained at 20/30 with no evidence of CNV recurrence. Our findings suggest that intravitreal ranibizumab may be an effective therapeutic option for treating CNV secondary to choroidal osteoma.
topic Ranibizumab
Choroidal osteoma
Choroidal neovascularization
url http://www.karger.com/Article/FullText/339624
work_keys_str_mv AT zenithhywu longtermfollowupofintravitrealranibizumabforthetreatmentofchoroidalneovascularizationduetochoroidalosteoma
AT michelleyywong longtermfollowupofintravitrealranibizumabforthetreatmentofchoroidalneovascularizationduetochoroidalosteoma
AT timothyyylai longtermfollowupofintravitrealranibizumabforthetreatmentofchoroidalneovascularizationduetochoroidalosteoma
_version_ 1725548336158605312